Dacomitinib

Category: Cancer



Dacomitinib Overview

Dacomitinib (PF-00299804) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1] Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals.[2][3][4] Additional Phase III trials are ongoing.[2] In 201...

Read more Dacomitinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dacomitinib

Recent Dacomitinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dacomitinib
  • Tablet: 15mg, 30mg, 45mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Dacomitinib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA